PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-57.23%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
5.53%
EBIT growth of 5.53% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
5.53%
Operating income growth of 5.53% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
5.62%
Net income growth of 5.62% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
13.79%
EPS growth of 13.79% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
13.79%
Diluted EPS growth of 13.79% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
10.10%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
10.10%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth of 18.75% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
17.73%
FCF growth of 17.73% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
94.36%
OCF/share CAGR of 94.36% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
80.21%
3Y OCF/share growth of 80.21% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-551.14%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.55%. Seth Klarman might see a fundamental problem if peers maintain growth.
94.20%
5Y net income/share CAGR > 1.5x Healthcare median of 11.76%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
81.22%
3Y net income/share CAGR > 1.5x Healthcare median of 5.93%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
1992.70%
Equity/share CAGR of 1992.70% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-67.70%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-15.48%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Asset growth of 12.46% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.36%
BV/share growth of 3.36% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-16.56%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-15.08%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-0.47%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.